|
|||||
|
|
| 一线应用紫杉醇联合萘达铂治疗晚期食管癌近期疗效观察 | |
| 引用本文： | 何义富,胡长路,徐腾云,范平生,蒋骑,张丽娟,朱磊,陈曼萍,季楚舒,胡冰. 一线应用紫杉醇联合萘达铂治疗晚期食管癌近期疗效观察[J]. 中华肿瘤防治杂志, 2011, 18(1): 60-62 |
| 作者姓名： | 何义富 胡长路 徐腾云 范平生 蒋骑 张丽娟 朱磊 陈曼萍 季楚舒 胡冰 |
| 作者单位： | 1. 安徽医科大学附属省立医院肿瘤内科,安徽,合肥,230001 2. 安徽省肿瘤医院肿瘤科,安徽,合肥,230031 |
| 基金项目： | 安徽省自然科学基金，2008年安徽省临床医学应用技术项目，2010年省卫生厅医学科研课题 |
| 摘 要： | 目的:观察紫杉醇联合萘达铂方案一线治疗晚期或手术/放疗后转移复发性食管癌患者的近期疗效和安全性。方法:给药方案为紫杉醇135~150 mg/m2,3 h静脉滴入,d1;萘达铂80 mg/m2,2 h静脉滴入,d2。每个周期为21 d。疗效评估用RECIST疗效评价标准;不良反应评估用NCI CTC 3.0标准。结果:有效率(RR)50.0%(14/28),稳定率(SD)35.7%(10/28),进展率(PD)14.3%(4/28)。主要不良反应有粒细胞细胞下降78.6%(3/4度21.4%),贫血57.1%(3/4度10.7%),血小板下降50.0%(3/4度10.7%),恶心60.7%(3/4度7.1%),呕吐50.0%(3/4度3.6%),2例(7.1%)患者推迟化疗但均≤1周,无治疗相关性死亡。结论:紫杉醇联合萘达铂治疗晚期或手术/放疗后转移复发性食管癌具有较好的疗效且有较好的耐受性。 |
| 关 键 词： | 食管肿瘤/药物疗法 紫杉酚 药物疗法,联合 |
Short-term response of paclitaxel and nedaplatin as first-line chemotherapy in patients with metastatic esophageal cancer |
|
| HE Yi-fu,HU Chang-lu,XU Teng-yun,FAN Ping-sheng,JIANG Qi,ZHANG Li-juan,ZHU Lei,CHEN Man-Ping,JI Chu-shu,HU Bing. Short-term response of paclitaxel and nedaplatin as first-line chemotherapy in patients with metastatic esophageal cancer[J]. Chinese Journal of Cancer Prevention and Treatment, 2011, 18(1): 60-62 | |
| Authors: | HE Yi-fu HU Chang-lu XU Teng-yun FAN Ping-sheng JIANG Qi ZHANG Li-juan ZHU Lei CHEN Man-Ping JI Chu-shu HU Bing |
| Affiliation: | HE Yi-fu1,HU Chang-lu1,XU Teng-yun1,FAN Ping-sheng2,JIANG Qi1,ZHANG Li-juan1,ZHU Lei2,CHEN Man-Ping1,JI Chu-shu1,HU Bing1 1.Department of Medical Oncology,Anhui Provincial Hospital Affiliated to Anhui Medical University,Hefei 230001,P.R.China2.Department of Medical Oncology,Anhui Provincial Cancer Hospital,Hefei 230031,P.R.China |
| Abstract: | OBJECTIVE: To investigate the efficacy and toxicity of the combination of paclitaxel and nedaplatin as first-line chemotherapy for patients with metastatic esophageal cancer.METHODS: Patients with metastatic esophageal cancer received 135-150 mg/m2 of paclitaxel over a 3 h infusion(d1),followed by nedaplatin 80 mg/m2 in a 2 h infusion(d2) every 3 weeks until the documented disease progression,unacceptable toxicity and patient's refusal.RECIST and NCT CTC 3.0 systems were used to evaluate treatment outcome a... |
| Keywords: | esophageal neoplasms/drug therapy paclitaxel drug therapy combination |
| 本文献已被 CNKI 万方数据 等数据库收录！ | |